Skip to Content
  • Previous Rank
    248
  • Revenues ($M)
    $12,273.90
  • Revenue Percent Change
    7.2%
  • Profits ($M)
    $2,539.10
  • Profits Percent Change
    -31.4%
  • Assets ($M)
    $23,652.60
  • Employees
    7,300
  • Market Value — as of March 29, 2018 ($M)
    $57,930.10

The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases, and hemophilia. It also makes and sells biosimilars of advanced biologics.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Michel Vounatsos
CEO Title
Chairman & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Cambridge, Mass.
Websitehttp://www.biogen.com
Years on Fortune 500 List9
Employees7,300

Biogen Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$12,273.907.2%
Profits ($M)$2,539.10-31.4%
Assets ($M)$23,652.60-
Total Stockholder Equity ($M)$12,612.80-
Market Value — as of March 29, 2018 ($M)$57,930.10-

Profit Ratios

Profit as % of Revenues20.7%
Profits as % of Assets10.7%
Profits as % of Stockholder Equity20.1%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)11.92
EPS % Change (from 2016)-29.6%
EPS % Change (5 year annual rate)15.7%
EPS % Change (10 year annual rate)19.6%

Total Return

Total Return to Investors (2017)21.8%
Total Return to Investors (5 year, annualized)18.7%
Total Return to Investors (10 year, annualized)19.8%